Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies

Medicine (Impact Factor: 5.72). 05/2014; 93(3):150-7. DOI: 10.1097/MD.0000000000000028
Source: PubMed


Necrotizing autoimmune myopathy (NAM) is a group of acquired myopathies characterized by prominent myofiber necrosis with little or no muscle inflammation. Recently, researchers identified autoantibodies (aAb) against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in patients with NAM, especially in statin-exposed patients. Here we report what is to our knowledge the first European cohort of patients with NAM.The serum of 206 patients with suspicion of NAM was tested for detection of anti-HMGCR aAb using an addressable laser bead immunoassay. Forty-five patients were found to be anti-HMGCR positive. Their mean age was 48.9 ± 21.9 years and the group was predominantly female (73.3%). Statin exposure was recorded in 44.4% of patients. Almost all patients had a muscular deficit (97.7%), frequently severe (Medical Research Council [MRC] 5 ≤3 in 75.5%). Subacute onset (<6 mo) was noted for most of them (64.4%). Nevertheless, 3 patients (6.6%) had a slowly progressive course over more than 10 years. Except for weight loss (20%), no extramuscular sign was observed. The mean CK level was high (6941 ± 8802 IU/L) and correlated with muscle strength evaluated by manual muscle testing (r = -0.37, p = 0.03). Similarly, anti-HMGCR aAb titers were correlated with muscular strength (r = -0.31; p = 0.03) and CK level (r = 0.45; p = 0.01). Mean duration of treatment was 34.1 ± 40.8 months, and by the end of the study no patient had been able to stop treatment.This study confirms the observation and description of anti-HMGCR aAb associated with NAM. The majority of patients were statin naive and needed prolonged treatments. Some patients had a dystrophic-like presentation. Anti-HMGR aAb titers correlated with CK levels and muscle strength, suggesting their pathogenic role.

75 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The spectrum of congenital myasthenic syndromes continues to expand, and recent studies found mutations in enzymes that glycosylate peptides. Affected patients have early onset of a limb-girdle pattern of weakness, and the disorder is treatment responsive. Another article addressed quinine use for slow channel syndrome. There is an additional report on the use of rituximab in acquired myasthenia gravis, and the risk of developing cancer with azathioprine therapy for myasthenia gravis is also covered. Regarding amyotrophic lateral sclerosis, we review articles addressing the utility and safety profile of botulinum injections for sialorrhea and possible associations with autoimmune diseases. Moving to peripheral nerve, we address reports on small fiber neuropathy as a cause of muscle cramps, reexamine clinical and electrodiagnostic features of childhood Guillain-Barré syndrome, and review a recent article on an unusual syndrome of postirradiation lower motor neuron syndrome affecting the cauda equina. Finally, recent reports show that mutations in the skeletal muscle ryanodine receptor may be a common cause of rhabdomyolysis and exertional myalgias and another cause of axial myopathy. Advances in clinical and basic science concepts of myotonic dystrophy are also reviewed.
    Journal of clinical neuromuscular disease 12/2013; 15(2):77-86. DOI:10.1097/CND.0000000000000016
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: This review discusses the spectrum of diseases associated with a necrotizing muscle biopsy. Although patients with toxic myopathies, endocrine dysfunction, and heritable myopathies may have prominent necrosis on muscle biopsy, immune-mediated myopathies are emphasized here. Recent findings: A decade ago, immune-mediated necrotizing myopathy was recognized as a distinct form of myositis. Recent evidence now suggests that immune-mediated necrotizing myopathy is not one disease, but can be divided on the basis of the presence of distinct autoantibodies recognizing either the signal recognition particle or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Anti-HMG-CoA reductase-positive patients can be further subdivided into those with and without statin exposure, the latter of which may be particularly refractory to immunosuppressive therapy. Summary: A significant number of patients with autoimmune myopathy have a predominantly necrotizing muscle biopsy with minimal lymphocytic infiltration. This biopsy finding occurs in various forms myositis, including the antisynthetase syndrome, scleroderma-associated myopathy, antisignal recognition particle-associated myopathy, statin-associated anti-HMG-CoA reductase-positive autoimmune myopathy, and statin-naïve anti-HMG-CoA reductase-positive myopathy. Future progress in elucidating pathogenic mechanisms and defining optimal treatment strategies may depend upon recognizing these distinct forms of myositis and analyzing them as separate entities.
    Current Opinion in Rheumatology 09/2014; 26(6). DOI:10.1097/BOR.0000000000000106 · 4.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Clinical registries and biorepositories have proven extremely useful in many studies of diseases, especially rare diseases. Given their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndromes, have benefited from individual researchers' collections of cohorts of patients. Major efforts are being made to establish large registries and biorepositories that will allow many additional studies to be performed that were not possible before. Here, we describe the registries developed by investigators and patient support groups that are currently available for collaborative research purposes. Recent findings: We have identified 46 myositis research registries, including many with biorepositories, which have been developed for a wide variety of purposes and have resulted in great advances in understanding the range of phenotypes, clinical presentations, risk factors, pathogenic mechanisms, outcome assessment, therapeutic responses, and prognoses. These are now available for collaborative use to undertake additional studies. Two myositis patient registries have been developed for research, and myositis patient support groups maintain demographic registries with large numbers of patients available to be contacted for potential research participation. Summary: Investigator-initiated myositis research registries and biorepositories have proven extremely useful in understanding many aspects of these rare and diverse autoimmune diseases. These registries and biorepositories, in addition to those developed by myositis patient support groups, deserve continued support to maintain the momentum in this field as they offer major opportunities to improve understanding of the pathogenesis and treatment of these diseases in cost-effective ways.
    Current Opinion in Rheumatology 09/2014; 26(6). DOI:10.1097/BOR.0000000000000119 · 4.89 Impact Factor
Show more

Similar Publications

Preview (2 Sources)

75 Reads
Available from